Antihypertensive medication
PreclinicalSmall molecule
Antihypertensive medication is one of 19 small molecule programs targeting Primary Aldosteronism. It is currently in Preclinical.
2
Indications
4
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in Primary Aldosteronism
#DrugCompanyPhaseTrials
1Kerendia
BayerApproved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Parlodel
VVeroScience
Approved
Baxfendy
AstraZenecaPhase 3
Aldactone
PfizerPreclinical
Adrenocorticotropic Hormone
AstellasPreclinical
Nifedipine ER
MMedical College of Wisconsin
Preclinical
Intensive BP Control
SSecond Affiliated Hospital of Nanchang University
Preclinical
Mineralocorticoid Receptor Antagonists
UUniversity of Pennsylvania
Preclinical
CS-3150
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Coronary Atherosclerosis1 trial
Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)
Unknown status·—·Phase 4·NCT02360956·100 enrolled
Transient Ischemic Attack1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antihypertensive medication. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Alberta